Express Pharma

SEPTEMBER 19, 2023

Venus Remedies has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs. billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 With this, the company has secured 511 marketing approvals for its oncology products across 66 countrles. per cent from 2021 to 2030.

Chemotherapy 103

Chemotherapy Compounding 103

European Pharmaceutical Review

FEBRUARY 21, 2024

TAGRISSO as a combination treatment with chemotherapy was recently approved in the US, based on data from the FLAURA2 Phase III trial. Research predicts 2029 small molecule oncology market leaders The post EGFR inhibitor could provide major advance in lung cancer appeared first on European Pharmaceutical Review.

Chemotherapy 84

Chemotherapy 84

Pharmaceutical Technology

MAY 12, 2023

The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload. GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). targeting ADC.

Chemotherapy 64

Chemotherapy Compounding 64

European Pharmaceutical Review

OCTOBER 26, 2023

Yet as the market continues to recognise the value of these treatments, especially with them having “clear benefits over current monotherapy and combination therapy options in cancer treatment”, it is unsurprising that GlobalData’s research predicted the ADC oncology therapy market will value more than $36 billion by 2029.

Chemotherapy 92

Chemotherapy Drug Development 92

Pharmaceutical Technology

JULY 8, 2022

Blincyto has provided a strong positive signal to demonstrate the clinical and commercial viability of BiTEs, with 2021 company-reported global sales of $542 million and GlobalData’s analyst consensus forecast projecting peak annual sales of $771 million by 2029, thereby sparking further industry interest in this field. months vs. 4.0

Chemotherapy 59

Chemotherapy Immunity Immunization 59

Express Pharma

FEBRUARY 21, 2024

billion by 2029. “ billion by 2029. “ billion in 2023, and GlobalData projects it to surpass $14 billion by 2029. The ADC contains an anti-TROP2 monoclonal antibody covalently linked to the topoisomerase I inhibitor cytotoxic payload. GlobalData estimates the drug to earn $3.12 GlobalData estimates the drug to earn $3.12

Chemotherapy 104

Chemotherapy Labelling Immunity Immunization 104